At what enterprise value was OPELLA acquired in 2024?

During the acquisition of OPELLA by CLAYTON, DUBILIER & RICE (CD&R) in 2024, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of OPELLA when it was acquired by CLAYTON, DUBILIER & RICE (CD&R)?

The estimated EV/EBITDA multiple for OPELLA is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was OPELLA acquired by CLAYTON, DUBILIER & RICE (CD&R)?

OPELLA was acquired by CLAYTON, DUBILIER & RICE (CD&R) in 2024.

What was the revenue of OPELLA at the time of the deal?

The revenue of OPELLA at the time of the deal is estimated to be in the range of 5b - 100b EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of OPELLA during the acquisition?

OPELLA's EBITDA is estimated to be in the range of 750M - 1.3b EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the OPELLA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the OPELLA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.boursorama.com/bourse/actualites/sanofi-bruxelles-autorise-la-vente-d-opella-a-l-americain-cd-r-faeeb85f4d18bd38e3f8ee53917d6546#:~:text=La%20valorisation%20d'Opella%20est,son%20Ebitda%20estim%C3%A9%20pour%202024

← DATABASE

Home Database Healthcare & PharmaOPELLA

10/2024

OPELLA acquired by CLAYTON, DUBILIER & RICE (CD&R)

FRANCE Life Sciences / Pharma & Biotech / Generics / Labs EV 3b - 100b EUR

Context

Sanofi has announced the sale of 50% of its stake in Opella to the American fund CD&R. Opella Healthcare (formerly Sanofi Consumer Healthcare) is a company specializing in consumer healthcare products.

OPELLA, which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Opella is a premier global leader in the consumer healthcare and self-care market, ranking as a top-3 worldwide player in the Over-the-Counter (OTC) medicines and Vitamins, Minerals & Supplements (VMS) segments. Formerly the consumer health division of pharmaceutical giant Sanofi, the company commands a high-heritage portfolio of leading global and localized brands, including Doliprane, Allegra, Dulcolax, Essentiale, and Enterogermina. Operating under an agile Fast-Moving Consumer Healthcare (FMCH) business model, the enterprise leverages a multi-channel commercial footprint across more than 100 countries, supported by 13 world-class manufacturing facilities and 4 specialized science & innovation hubs.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2024	NEXTSTAGE / IK PARTNERS	EUROBIO SCIENTIFIC	FRANCE	Diagnostic Equipment
11/2024	NAXICAP PARTNERS	GLOBAL D	FRANCE	Implants & Prosthetics
10/2024	BANSK GROUP	PETIQ	UNITED STATES	Animal Health
10/2024	KKR / KREFELD	ANJAC BEAUTY & HEALTH	FRANCE	CDMO
09/2024	AGILENT TECHNOLOGIES	BIOVECTRA	CANADA	CDMO
08/2024	RECURSION PHARMACEUTICALS	EXSCIENTIA	UNITED KINGDOM	R&D Biotech
08/2024	NORDSON CORPORATION	ATRION CORPORATION	UNITED STATES	Diagnostic Equipment
07/2024	ROCHE	LUMIRADX	UNITED KINGDOM	Diagnostic Equipment
05/2024	BRUKER	ELITECH GROUP	FRANCE	Diagnostic Equipment
05/2024	GTCR	SURMODICS	UNITED STATES	Medical Devices

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 5b - 100b EUR

EBITDA range: 750M - 1.3b EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OPELLA by CLAYTON, DUBILIER & RICE (CD&R) are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: opella

Acquirer: clayton, dubilier & rice (cd&r)